Don't want ads? Subscribe or login now.

Nixed Pfizer Inversion Casts Uncertainty On Similar Deals

By Chelsea Naso · April 6, 2016, 7:52 PM EDT

Pfizer's scrapped plans for its record $160 billion corporate inversion with Irish drugmaker Allergan may be just one casualty of the U.S. Department of Treasury's latest rulemaking, but the thwarted deal...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Chelsea

December 19, 2019
The Biggest M&A Moments Of 2019's Second Half
June 11, 2019
H&R Block Inks $405M Wave Financial Buy
May 02, 2019
Apollo Joins Wave Of Firms Converting To C Corp. Structure
May 29, 2018
Baker Botts Steers Kimbell In $404M PE-Backed Royalty Deal
March 23, 2018
Broadcom Investors OK Plan To Move Domicile Back to US
August 30, 2017
Trump Tax Talk's Few Details Let M&A Uncertainty Persist
April 28, 2017
Trump's Corporate Tax Reform Poised To Fuel More M&A
December 12, 2016
Deals That Died In 2016 And What Killed Them
November 15, 2016
IRS Aims To Block NAM Brief In Anti-Inversion Rule Fight
October 17, 2016
US Election Will Shake Up Activism, Okapi CEO Says

Nixed Pfizer Inversion Casts Uncertainty On Similar Deals

Related Sections

Recent Articles By Chelsea